Abstract. Inhibin β A (INHBA) is a member of the transforming growth factor β (TGF-β) superfamily. INHBA expression is associated with several types of human cancers; however, its significance in colorectal cancer (CRC) is not fully understood. INHBA expression was studied in 126 primary CRC samples and 4 CRC cell lines. Cell growth was assessed after inhibition of INHBA expression or after exogenous overexpression of INHBA in CRC tissues. INHBA expression was significantly higher in CRC tissues when compared to that in the corresponding normal tissues (P<0.001). Patients in the high expression group showed a poorer overall survival rate when compared to those in the low expression group (P<0.001); the present study did not evaluate for an independent prognostic factor but showed the significance of lymph node metastasis as an independent prognostic factor. The present study suggests that INHBA is useful as a predictive marker for prognosis in CRC patients.
Introduction
In many developed countries, cancer is one of the most common causes of death. The incidence of colorectal cancer (CRC) has recently increased in Japan, in concert with changing lifestyles (1) . The major cause of death from cancer is distant metastases. Identification of genes responsible for development and progression of CRC and understanding their clinical significance are critical for the establishment of adequate treatments for this disease (2, 3) .
Inhibin β A (INHBA) is a member of the transforming growth factor β (TGF-β) superfamily (4) . INHBA forms a disulfide-linked homodimer known as activin A, which was originally described in 1978 for its role in the hypothalamicpituitary-gonadal axis (5, 6) . It is able to strongly induce embryonic stem cell differentiation (7) . Its expression is increased in carcinoma tissues, as established by studies of activin A levels in esophageal (8) , pancreatic (9) , prostate (10) , and ovarian (11, 12) cancers, and patients with endometrial and cervical carcinomas have high serum levels of activin A (13) .
The aim of this study was to analyze the correlation between INHBA expression in CRC tissues obtained from patients and clinicopathological factors. In addition, we performed an in vitro study in which gene knockdown techniques and the introduction of INHBA were used to investigate the relevance of INHBA expression and its relationship with clinicopathological characteristics.
Materials and methods
Cell culture. Human CRC cell lines (CaR1, CCK81 and DLD-1) were obtained and cultured in minimum essential medium (MEM; Invitrogen Life Technologies, Carlsbad, CA, USA) containing 10% fetal bovine serum (FBS; Gibco-BRL, Carlsbad, CA, USA) and antibiotics at 37˚C in a humidified atmosphere containing 5% CO 2 . Caco-2 cells were cultured in MEM containing 20% FBS. For the small interference RNA (siRNA) knockdown experiment, RNA duplexes that targeted human INHBA (5' end) were synthesized (Hs_INHBA_4HPsiRNA; Qiagen, Valencia, CA, USA). AllStars Neg siRNA was used as a negative control (sense sequence, UUCUCCGAACGUGUCACGU; Qiagen). CRC cell lines were transfected with 15 µmol/l siRNA using HiPerFect transfection reagent (Qiagen). The growth rate of the cell culture was measured by counting cells using a CellTac kit (Nihon Koden, Tokyo, Japan). Triple transfection was performed using all the siRNA duplexes together. RNA study. Total RNA was extracted from the frozen tissues, and reverse transcription was performed (16, 17) . Two human INHBA oligonucleotide primers used for PCR were designed as 238-bp INHBA fragments [5'-CCTCGGAGATCATCACG TTT-3' (forward) and 5'-CCCTTTAAGCCCACTTCCTC-3' (reverse)]. The forward primer was located in exon 1, and the reverse primer was located in exon 2. As an internal control, a PCR assay was performed using primers specific to glyceraldehyde-3-phosphate dehydrogenase (GAPDH). These GAPDH primers, 5'-TTGGTATCGTGGAAGGACTCA-3' (forward) and 5'-TGTCATCATATTGGCAGGTT-3' (reverse), produced a 270-bp amplicon. Real-time PCR monitoring was performed using the LightCycler system (Roche Diagnostics, Tokyo, Japan) for complementary DNA (cDNA) amplification of INHBA and GAPDH. The amplification protocol consisted of 40 cycles of denaturation at 95˚C for 10 sec, annealing at 60˚C for 10 sec, and elongation at 72˚C for 10 sec. The PCR products were then subjected to a temperature gradient from 55˚C to 95˚C at 0.1˚C sec -1 with continuous fluorescence monitoring to produce product melting curves. The mRNA expression ratio of tumor to normal tissues was calculated and normalized against GAPDH mRNA expression.
Statistical analysis. For continuous variables used in an
in vitro analysis, data are expressed as means ± SD and were analyzed using the Wilcoxon rank test. The relationship between mRNA expression and clinicopathological factors was analyzed using the Chi-square and Student's t-tests.
Kaplan-Meier survival curves were plotted and compared using a generalized log-rank test. Univariate and multivariate analyses for the identification of factors prognostic for overall survival were performed using the Cox proportional hazard regression model. All tests were analyzed using JMP software (SAS Institute Inc., Cary, NC, USA). P-values of <0.05 were considered statistically significant.
Results

INHBA mRNA expression in CRC clinical tissue specimens and clinicopathological characteristics.
We performed quantitative real-time RT-PCR analysis using primary CRC and adjacent noncancerous CRC tissues. RT-PCR of 126 paired clinical samples showed that 116 (92.1%) of these samples exhibited higher INHBA mRNA levels in tumor tissues than in paired normal tissues (Fig. 1A) . INHBA expression was calculated as INHBA/GAPDH expression. For the evaluation of clinicopathological factors, the tissue samples were divided into 2 groups according to INHBA expression. Patients with tumors that had a more than median INHBA expression were assigned to the high expression group (n=63); the others were assigned to the low expression group (n=63). Clinicopathological factors related to the INHBA expression status of the 126 patients are summarized in Table I . The data indicated that INHBA expression was correlated with the tumor stage (P<0.0001), lymph node metastasis (P<0.0001), lymphatic invasion (P= 0.0013), venous invasion (P<0.0001) and liver metastasis (P= 0.0024). Other factors were not significantly correlated with INHBA expression.
Relationship between INHBA expression and prognosis. The data showed that the overall survival rate was significantly lower in the high expression group than in the low expression group (P=0.0016) (Fig. 1B) . The median follow-up period was 3.33±2.67 years. In vitro assessment of knockdown and transfection of INHBA. The INHBA expression study indicated that CaR1 cells had higher levels of expression than other CRC cell lines such as DLD1, Caco-2 and CCK81 ( Fig. 2A) . We performed a knockdown experiment of INHBA expression using the CaR1 cell line. After 48 h of siRNA transfection, quantitative real-time RT-PCR was used to confirm the reduction in INHBA expression due to siRNA treatment (Fig. 2B) . A proliferation assay indicated that the knockdown resulted in a reduction in the number of CaR1 cells at 72 h (P<0.05; Fig. 2C ). We induced INHBA expression in the cell lines (DLD1, Caco-2 and CCK81) using a plasmid technique, and quantitative real-time RT-PCR confirmed successful induction in them (Fig. 3A-C) . Proliferation assays indicated that high INHBA expression increased the cell numbers of CRC cells, which have low INHBA expression by default (P<0.05; Fig. 3D-F) at 48 h.
INHBA/GAPDH expression ---------------------------------------------
Discussion
INHBA is a subunit of both activin and inhibin, two closely related glycoproteins with opposing biological effects, which belong to the TGF-β superfamily (18) (19) (20) . The TGF-β superfamily comprises a structurally similar, although functionally diverse group of proteins that play important roles in embryonic development as well as in the functions of terminally differentiated tissues. Activins play fundamental roles in cell differentiation and development and are known to induce cellular responses via activin receptors and the SMAD2/3 pathway, while inhibits function to antagonize activins through either competition of receptor binding or β-glycan.
In the present study, we determined that INHBA is highly expressed in CRC tissues when compared with that in the corresponding normal tissues. In addition, high INHBA expression in CRC tissues was a predictor of poor prognosis when compared with low INHBA expression. Clinicopathological factors related to the INHBA expression status indicated that the high expression group displayed a worse histological grade, higher tumor stage, more lymph node metastasis, poorer lymphatic invasion, greater vascular invasion and more extensive liver metastasis. Therefore, INHBA expression was not an independent prognostic factor but may be strongly related to one of the other prognostic factors of CRC. Thus, this study of the association of high INHBA expression with other prognostic factors indicated that high INHBA expression is an independent prognostic factor for lymph node metastasis. Inclusion in the INHBA mRNA high expression group was an independent predictor of lymph node metastasis, as was lymphatic invasion. The overexpression and knockdown experiments were performed in vitro. These experiments showed that high INHBA expression induced cell growth, whereas low INHBA expression induced an opposite effect.
It is useful to determine the necessity for intensive followup and adjuvant therapy for CRC by predicting recurrence and metastases after curative surgical resection (21) (22) (23) . In the present study, clinicopathological analysis revealed that patients who had CRCs with high INHBA expression had a poor prognosis for overall survival than those with low expression. The data indicated that INHBA expression is presumably a novel predictor of CRC prognosis. Several adjuvant chemotherapies are helpful at certain disease stages, particularly in CRC (23) (24) (25) (26) (27) . For such cases, an informative prognostic marker, which is independent of the traditional TNM classification, is extremely important and can contribute to diagnosis and treatment. Adjuvant chemotherapy for CRC is necessary for highly suspicious recurrent cases. In such cases, analysis of INHBA expression may be useful for predicting CRC prognosis, and INHBA is also proposed to be a therapeutic target in treatment for patients with poor prognosis.
